Please login to the form below

Not currently logged in
Email:
Password:

US generics face competition from India

Indian companies have accounted for 35 per cent of all abbreviated new drug application approvals so far this year

Indian companies have accounted for 35 per cent of all abbreviated new drug application (ANDA) approvals so far this year, according to industry information portal, fiercepharma.com. Besides Ranbaxy, which is under Food and Drug Administration (FDA) investigation for falsifying data on its applications, all of the top Indian drugmakers have maintained or improved their approval rates. Sun Pharma received 30 ANDA approvals in 2008, up from 20 in 2007, and Wockhardt was awarded 18 in 2008, against 13 the previous year. Dr Reddy's obtained 14 approvals in 2008, from 13 in 2007. Meanwhile, Flamingo Pharmaceuticals has said it plans to introduce 20 new generics over the next six months, and is making improvements to its distribution network to facilitate its growth.

The rate of approvals is set to continue to increase following the FDA opening an office in Delhi in January. Seven FDA staff will be based in Delhi and three in Mumbai.

9th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics